Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyridium and Riboflavin for Ureteral Jet Visualization
NCT03432572Phase 1Completed
- Sponsor
- Texas Tech University Health Sciences Center
- Start
- Jun 2018
- Primary completion
- Jun 2020
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of phenazopyridine and riboflavin in ureteral injury, sponsored by Texas Tech University Health Sciences Center. Primary endpoint: Urine discoloration on cystoscopy. Started Jun 2018; status: completed.
02
Drugs
phenazopyridineriboflavin
03
Conditions
ureteral injury
Beyond the preview
Go deeper on NCT03432572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03432572.